Connect with us

INDUSTRIAL HEMP

AbbVie Inc (NYSE:ABBV) Upadacitinib Demonstrates Positive Data As Monotherapy In Phase III Rheumatoid Arthritis Trial

Published

on

AbbVie Inc (NYSE:ABBV) posted positive top-line data from the Phase III SELECT-MONOTHERAPY clinical study. This ongoing trial assessed upadacitinib as a monotherapy treatment in people with moderate-to-severe rheumatoid arthritis who failed to adequately respond to methotrexate treatment.

The details

Results demonstrated that following 14 weeks of treatment, once-daily doses of upadacitinib met the trial’s primary endpoints of ACR20 and low disease activity against continuing prior stable methotrexate treatment. Both doses achieved all key secondary objectives. Upadacitinib is not permitted by regulatory authorities and its efficacy and safety have not been set. Michael Severino, M.D., the EVP, R&D and Chief Scientific Officer at AbbVie, reported that the positive data from the SELECT-MONOTHERAPY trial are promising, as they are the initial evidence to support the prospect of upadacitinib as a treatment without the requirement for background methotrexate.

This report adds to the increasing body of data demonstrating the potential for upadacitinib as a notable treatment option for people struggling with rheumatoid arthritis. Severino added that they look forward to releasing additional results from the upadacitinib Phase III rheumatoid arthritis plan with the scientific community next year.

Josef S. Smolen, M.D., An investigator in the trial, expressed that this study addresses the clinical impact of moving to upadacitinib from methotrexate as monotherapy in people with unsatisfactory response to methotrexate. Data indicated that both doses of upadacitinib can offer clinically notable responses. The latest data advances the potential for upadacitinib as a monotherapy treatment alternative for patients with rheumatoid arthritis.

RA, which affects a projected 23.7 million people globally, is a debilitating and chronic disease. Methotrexate is usually used as a first-line treatment in rheumatoid arthritis, however many patients cannot tolerate or do not respond to methotrexate, which places them at peril for disease progression.

In the last trading session, the stock price of AbbVie gained 0.35% to close at $98.09.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement